Overall verdict
Neutral
6.2/10
1-year performance
+112.65%
Score breakdown
Up 112.7% over 1 year, 75% of the 52-week range.
Strongest: Growth 9.5/10. Weakest: Shareholder return 0.0/10.
11 analysts, target +0.2% vs the price.
Oscar Health, Inc. operates as a healthcare technology company in the United States. The company offers health plans to individuals, families, employees, and small group markets. It also provides +Oscar platform that power others throughout the healthcare system; Campaign Builder platform, an engagement and recommendation platform for providers and payors; and reinsurance products.
In addition, the company offers brokerage services and enrollment platform for brokers and consumers to shop, buy, and enroll in medical and supplemental health products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was incorporated in 2012 and is headquartered in New York, New York.
Sector
Financials
Industry
Insurance
Primary listing
Nyse
United States
CEO
Mark Bertolini
Founded
2012
Employees
2 305
Revenue / employee
5.1M USD
Next earnings
February 5, 2027 (estimated)
Institutional holders
- FMR LLC3.29%
- GEODE CAPITAL MANAGEMENT, LLC2.60%
- Bank of New York Mellon Corp0.30%
- Rest of the register93.82%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
38.50 USD
52-week low
10.69 USD
1-year performance
112.65%
Rising
Year-to-date performance
119.27%
Rising
Drawdown
-17.70%
Marked drawdown
Position in the 52-week range
75% of range
Range: 32.55 USD - 49.00 USD (2 methods agree)
The price implies growth of -28.87% per year; the company grows at 25.00%.
Net margin 4.9%, ROE 52.7%.
Net margin
4.90%
Fair
Sector 6.54%|S&P 13.40%
Gross margin
—
Return on equity (ROE)
52.70%
Exceptional
Sector 12.03%|S&P 17.06%
Return on invested capital (ROIC)
39.19%
Free cash flow margin (FCF)
23.70%
Profit-to-cash conversion (FCF conversion)
4.84x
Margin stability
30.1 pts
Very uneven
Revenue to net income
Growth
9.5/10Revenue up 72.1% over 1 year, 90.8% a year over 5.
Revenue (trailing 12 months)
17.5Md USD
Revenue growth (1y)
72.11%
Hyper-growth
Revenue growth (3y)
195.22%
Hyper-growth
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
37.45%
Sharply revised up
Valuation
6.4/10P/E 13.3x, forward P/E 13.9x, PEG 0.07.
P/E (TTM)
13.3x
Fair
Sector 13.7x|S&P 23.6x
Forward P/E
13.9x
Expensive
EV / EBITDA
—
Sector 79.1x|S&P 15.5x
PEG
0.07
Growth unpriced
Sector -0.20|S&P 0.91
Fair value (reverse DCF)
39.93 USD
Undervalued
Market cap
8.7Md USD
Not scored for a bank or an insurer: its solidity is measured by regulatory capital ratios, which we do not collect.
Net debt / EBITDA
—
Gearing (net debt / equity)
-181.26%
Cash
4.5Md USD
Cash / market cap
51.55%
Cash / total debt
1033.01%
Interest coverage
68.3x
Net debt
-4.0Md USD
Equity
2.2Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 33.47 USD
- MM2032.29
- MM5031.94
- MM20024.18
- RSI 1454.7
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+7.64%
200-day average slope, 3 months
+25.53%
50-day average slope, 1 month
+2.69%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
4.11 % per day
Volatility change
+9.95%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 2.28 (6) | 2.33 (6) | 19 057 (9) | 1 028 (5) | 849 (3) |
| 2027 | 2.40 (6) | 2.36 (7) | 21 094 (10) | 1 081 (8) | 833 (4) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 9, 2026.
Same sub-industry: 81 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MET | 7.2 | 7.2 | 64.7Md USD | 13.4x | 6.2 % | 19.4 % | — | — | — | 33.0 % | ||
| 2 | 2628 | 7.1 | 8.8 | 132Md USD | 2.4x | 41.3 % | 36.2 % | — | — | — | -22.3 % | ||
| 3 | 601318 | 6.7 | 7.3 | 136Md USD | — | — | 6.5 % | — | — | — | -10.3 % | ||
| 4 | 1299 | 6.2 | 5.7 | 105Md USD | 13.3x | 23.2 % | 10.0 % | — | — | — | -4.8 % | ||
| 5 | OSCR | 6.2 | 6.6 | 8.7Md USD | 13.3x | 4.9 % | 72.1 % | — | — | — | 112.7 % | ||
| 6 | MFC | 5.8 | 4.7 | 72.8Md USD | 18.1x | 10.3 % | -31.3 % | — | — | — | 35.3 % | ||
| 7 | GWO | 5.7 | 4.8 | 59.1Md USD | 19.6x | 11.4 % | -67.1 % | — | — | — | 59.3 % | ||
| 8 | 2881 | 5.5 | 4.7 | 65.1Md USD | 13.7x | 18.1 % | -2.8 % | — | — | — | 73.8 % | ||
| 9 | AFL | 4.4 | 3.8 | 62.9Md USD | 18.5x | 21.2 % | -31.0 % | — | — | — | 11.4 % |
